A pilot trial to examine feasibility of a pharmacist-led intervention for patients with COPD (Chronic Obstructive Pulmonary Disease) and multimorbidity to improve medication safety and reduce dyspnea. Patients will receive inhaler teaching and medication optimization counseling. Outcomes include feasibility, acceptability, appropriateness, and exploratory measures such as medication discontinuation and patient-reported symptom burden.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
92
In-clinic or telehealth pharmacist visit for inhaler teaching, medication optimization, and deprescribing counseling; includes follow-up at weeks 4 and 12.
Proportion of eligible patients recruited to the intervention
A measure of feasibility of the intervention.
Time frame: Through the end of enrollment period, up to approximately 1 year
Acceptability of Intervention Measure (AIM)
The AIM is comprised of 4 items rated on a 5-point Likert scale, where the total score ranges from 4 to 20. A higher score indicates greater acceptability.
Time frame: Baseline, 4 weeks, 12 weeks
Feasibility of Intervention Measure (FIM)
The FIM is comprised of 4 items rated on a 5-point Likert scale, where the total score ranges from 4 to 20. A higher score indicates greater feasibility.
Time frame: Baseline, 4 weeks, 12 weeks
Intervention Appropriateness Measure (IAM)
The IAM is comprised of 4 items rated on a 5-point Likert scale, where the total score ranges from 4 to 20. A higher score indicates greater appropriateness.
Time frame: Baseline, 4 weeks, 12 weeks
Modified Medical Research Council (mMRC) questionnaire to measure dyspnea
The mMRC dyspnea scale is a 5-grade (0 to 4) questionnaire that measures the severity of breathlessness in daily activities, commonly used for assessing functional disability in COPD and other respiratory diseases. A higher score indicates greater, more incapacitating breathlessness.
Time frame: Baseline, 4 weeks, 12 weeks
Medication side effect burden, measured via Living with Medicines Questionnaire (LMQ-3)
Medication side effect burden refers to the physical, emotional, and practical impact of adverse drug reactions, often causing reduced quality of life, non-adherence, and treatment discontinuation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, 4 weeks, 12 weeks
Shared Decision Making (SDM-Q-9) questionnaires
The SDM-Q-9 has a total score range of 0 to 45, where a higher score indicates greater shared decision-making between patients and providers.
Time frame: Baseline, 4 weeks, 12 weeks